Treatment Preference and Patient Centered Prostate Cancer Care
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 800
Inclusion Criteria
- Provide informed consent
- Newly diagnosed with non-metastatic prostate cancer
- Has not yet started radiation or surgery
- Provide informed consent
- Newly diagnosed with non-metastatic prostate cancer
- Has not yet started radiation or surgery
Exclusion Criteria
- Distant, metastatic prostate cancer at diagnosis
- Has already begun treatment for prostate cancer
- Unable to communicate in English
- Distant, metastatic prostate cancer at diagnosis
- Has already begun treatment for prostate cancer
- Unable to communicate in English
Summary
- Conditions
- Prostate Cancer
- Type
- Interventional
- Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
The objective is to test the comparative effectiveness of a conjoint analysis decision aid intervention compared to usual care. The investigators will identify preferred attributes of prostate cancer treatments that will help in designing a conjoint analysis decision aid to help patients weigh treat...
The objective is to test the comparative effectiveness of a conjoint analysis decision aid intervention compared to usual care. The investigators will identify preferred attributes of prostate cancer treatments that will help in designing a conjoint analysis decision aid to help patients weigh treatment attributes. The investigators will employ values markers to represent clusters of values for particular aspects of treatments that are valued most by individual patients. The investigators will test if the concordance between values markers and treatment received is predictive of objective outcomes and subjective outcomes. The study hypothesis is that conjoint task may help in treatment choice and prostate cancer patients whose treatment is more concordant with their values markers will have improved outcomes.
Inclusion Criteria
- Provide informed consent
- Newly diagnosed with non-metastatic prostate cancer
- Has not yet started radiation or surgery
- Provide informed consent
- Newly diagnosed with non-metastatic prostate cancer
- Has not yet started radiation or surgery
Exclusion Criteria
- Distant, metastatic prostate cancer at diagnosis
- Has already begun treatment for prostate cancer
- Unable to communicate in English
- Distant, metastatic prostate cancer at diagnosis
- Has already begun treatment for prostate cancer
- Unable to communicate in English
Tracking Information
- NCT #
- NCT02032550
- Collaborators
- Patient-Centered Outcomes Research Institute
- Corporal Michael J. Crescenz VA Medical Center
- Fox Chase Cancer Center
- Investigators
- Principal Investigator: Ravishankar Jayadevappa, PhD University of Pennsylvania
- Ravishankar Jayadevappa, PhD University of Pennsylvania